Perioperative Nivolumab in Resectable Lung Cancer
New England Journal of Medicine · 16.05.2024 · 390 (19) · 1756-1769
DOI: 10.1056/nejmoa2311926 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift New England Journal of Medicine, erschienen am 16.05.2024. Verfasst von Tina Cascone und 29 weiteren Autor:innen. Beteiligte Einrichtung: From the University of Texas M.D. Anderson Cancer Center, Houston (T.C., B.S.); Dana-Farber Cancer Institute, Boston (M.M.A.); McGill University Heal…. Hauptthemen laut MEDLINE: Nivolumab, Lung Neoplasms, Carcinoma, Non-Small-Cell Lung, Neoadjuvant Therapy. Die Arbeit wurde bisher 567-mal zitiert (Crossref) und nennt 24 Literaturangaben. Gefördert von: Bristol Myers Squibb.
Abstract (Originalsprache)
BACKGROUND: Standard treatment with neoadjuvant nivolumab plus chemotherapy significantly improves outcomes in patients with resectable non-small-cell lung cancer (NSCLC). Perioperative treatment (i.e., neoadjuvant therapy followed by surgery and adjuvant therapy) with nivolumab may further improve clinical outcomes. METHODS: In this phase 3, randomized, double-blind trial, we assigned adults with resectable stage IIA to IIIB NSCLC to receive neoadjuvant nivolumab plus chemotherapy or neoadjuvant chemotherapy plus placebo every 3 weeks for 4 cycles, followed by surgery and adjuvant nivolumab or placebo every 4 weeks for 1 year. The primary outcome was event-free survival according to blinded independent review. Secondary outcomes were pathological complete response and major pathological response according to blinded independent review, overall survival, and safety. RESULTS: At this prespecified interim analysis (median follow-up, 25.4 months), the percentage of patients with 18-month event-free survival was 70.2% in the nivolumab group and 50.0% in the chemotherapy group (hazard ratio for disease progression or recurrence, abandoned surgery, or death, 0.58; 97.36% confidence interval [CI], 0.42 to 0.81; P
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- From the University of Texas M.D. Anderson Cancer Center, Houston (T.C., B.S.); Dana-Farber Cancer Institute, Boston (M.M.A.); McGill University Health Centre, Montreal (J.D.S.); the National Cancer Center-National Clin…
ORCID-Profile: Robin Cornelissen
Förderung
- Bristol Myers Squibb
Zitieren
APA
Cascone, T., Awad, M. M., Spicer, J. D., He, J., Lu, S., Sepesi, B., Tanaka, F., Taube, J. M., Cornelissen, R., Havel, L., Karaseva, N., Kuzdzal, J., Petruzelka, L. B., Wu, L., Pujol, J. L., Ito, H., Ciuleanu, T. E., de Oliveira Muniz Koch, L., Janssens, A., …, & CheckMate 77T Investigators (2024). Perioperative Nivolumab in Resectable Lung Cancer. New England Journal of Medicine, 390(19), 1756-1769. https://doi.org/10.1056/nejmoa2311926
Vancouver
Cascone T, Awad MM, Spicer JD, He J, Lu S, Sepesi B, et al. Perioperative Nivolumab in Resectable Lung Cancer. New England Journal of Medicine. 2024;390(19):1756-1769. doi:10.1056/nejmoa2311926
BibTeX
@article{Cascone2024,
author = {Cascone, Tina and Awad, Mark M and Spicer, Jonathan D and He, Jie and Lu, Shun and Sepesi, Boris and Tanaka, Fumihiro and Taube, Janis M and Cornelissen, Robin and Havel, Libor and Karaseva, Nina and Kuzdzal, Jaroslaw and Petruzelka, Lubos B and Wu, Lin and Pujol, Jean-Louis and Ito, Hiroyuki and Ciuleanu, Tudor-Eliade and de Oliveira Muniz Koch, Ludmila and Janssens, Annelies and Alexandru, Aurelia and Bohnet, Sabine and Moiseyenko, Fedor V and Gao, Yang and Watanabe, Yasutaka and Coronado Erdmann, Cinthya and Sathyanarayana, Padma and Meadows-Shropshire, Stephanie and Blum, Steven I and Provencio Pulla, Mariano and CheckMate 77T Investigators, CheckMate 77T Investigators},
title = {Perioperative Nivolumab in Resectable Lung Cancer},
journal = {New England Journal of Medicine},
year = {2024},
volume = {390},
number = {19},
pages = {1756--1769},
doi = {10.1056/nejmoa2311926}
}
EUVIMED